Facebook Twitter Linkedin

Inimmune attends BIO International Convention and provides an update on company programs and transition to a clinical stage biotech company.

Missoula, MT, June 5, 2023 – Inimmune, a leading biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, announced today that its Chief Scientific and Strategy Officer, Jay Evans, Ph.D., will provide an update on company programs and clinical trials on May 5th at BIO International Convention in Boston, MA (https://www.bio.org/events/bio-international-convention).

Inimmune has accrued a deep pipeline of innovative vaccines, adjuvants, and immunotherapy assets poised for rapid development and clinical advancement. Two of these assets are entering Phase I human clinical trials in mid and late 2023, targeting seasonal allergic rhinitis and immuno-oncology. This will be followed by additional clinical trials in 2024 for vaccines targeting opioid addition and infectious diseases.

“This is a transformative year for Inimmune as we make the transition from a pre-clinical to clinical stage biotech company” said Alan Joslyn, CEO of Inimmune. “Inimmune scientists are advancing novel vaccines and immunotherapies in areas of critical importance to global health.” BIO is the world largest advocacy association representing companies, academic and private research institutions, and state/national biotechnology organizations across the world. Each year these organizations come together at the BIO International Convention for networking, partnering, and education. Inimmune is a member of BIO and actively participates at the Convention through partnering meetings and company updates.

About Inimmune:

Inimmune Corp. (Missoula, MT) is a privately held biotechnology company focused on the discovery and development of innovative immunotherapeutics, vaccine adjuvants and vaccines. Inimmune is harnessing the human immune system to create safe and effective treatments for allergy, infectious disease, autoimmunity and cancer. Their laboratories and offices are housed in the Montana Technology Enterprise Center (MonTEC) in Missoula.
For more information on Inimmune’s research and development of novel vaccine adjuvants and delivery
systems, please visit www.inimmune.com.

Contact:
Media Relations
Inimmune Corporation
Phone: (406)-541-5913
Email: info@inimmune.com

Inimmune is a promising new biotechnology company founded by pharmaceutical industry veterans, focused on developing the next generation of vaccines and immunotherapeutics.

Facebook-f Twitter Linkedin

Quick Links

Contact

  • 1121 E Broadway St, Ste 106, Missoula, MT, 59802
  • 406-541-5913
  • info@inimmune.com

© Copyright 2022 Inimmune. All Rights Reserved.

Website Design by Digital Marketing Missoula
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go
Inimmune Oncology

Cancer Immunotherapy

Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Read More
Go

Adjuvants

Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovery of new adjuvants that target STING as well as inflammasome-activating adjuvants.
Read More
Go
inimmune-infectios-disease

Infectious Disease

Inimmune is at the forefront of infectious disease prevention and treatment through the development of cutting edge vaccines and antibiotics.
Read More
Go

Allergy

At Inimmune, we’re developing a rapid disease modifying treatment which does not require identification of the allergen. INI-2004 is an allergen agnostic immunotherapy that reprograms the allergic immune response, desensitizing the patient against allergens of concern.
Read More
Go

Autoimmunity

Inimmune is developing technology that turns off signaling from specific receptors that are involved in the development and maintenance of autoimmune disease.
Read More
Go
autoimmunity

Vaccines

To combat the opioid epidemic and the growing problem of drug resistant bacteria Inimmune is developing novel vaccines adjuvanted with our proprietary innate immune stimulators.
Read More
Go

TLR-7/8 (INI-4001), TLR-4 (INI-2002), CTLR (UM-1098), STING